Malcisbo AG

Malcisbo AG is a biotechnology firm dedicated to developing innovative vaccines that effectively target bacterial infections in livestock, particularly in poultry and swine farming. Founded in 2010 and based in Schlieren, Switzerland, Malcisbo AG focuses on creating vaccines to combat bacterial infections. The company has completed a total of one deal, with its latest funding round occurring in September 2011. The company is led by CEOs Bruno Oesch and Lino Camponovo.

Malcisbo AG specializes in the development of innovative vaccines designed to combat bacterial infections in livestock, focusing on farming animals. Utilizing a novel glycoengineering platform, the company aims to prevent diseases caused by pathogens such as Campylobacter and Actinobacillus pleuropneumonia. These vaccines are intended for use in poultry and swine, addressing health challenges in the farming industry while contributing to the reduction of antibiotic usage. The company's core offerings serve agricultural sectors in various geographical markets, specifically targeting regions with intensive animal farming, ensuring a wide reach among farmers and livestock producers.

Malcisbo AG generates revenue through direct sales of its vaccine products to agricultural entities, including farms and livestock producers. The company engages in B2B transactions, establishing partnerships with distributors and retailers in the agricultural sector to facilitate product accessibility. Revenue is supplemented by strategic collaborations with industry stakeholders focused on advancing veterinary health solutions. Specific pricing structures for the vaccines are not disclosed, but the company’s offerings are designed to provide cost-effective solutions for its clients, enhancing animal health while minimizing reliance on antibiotics.

Looking ahead, Malcisbo AG plans to develop new vaccine products designed to target additional bacterial pathogens, although specific release dates have not been disclosed. The company is also focusing on expanding its market presence in regions experiencing growth in livestock farming, with particular emphasis on European and Asian markets. The funding raised in September 2011 from Redalpine Venture Partners will be utilized to support these initiatives, specifically in product development and market expansion efforts.